BrainsWay 第四季度的收益超出预期，由于分析师维持“买入”评级，提振了其股价。 BrainsWay's Q4 earnings beat estimates, boosting its stock as analysts maintain a "buy" rating.

脑水公司是一家专门从事精神疾病神经刺激治疗的公司,报告Q4 EPS为0.08美元,比分析师的估计数高出0.05美元。 BrainsWay, a company specializing in neurostimulation treatments for mental health disorders, reported a Q4 EPS of $0.08, exceeding analysts' estimates by $0.05. 该公司的股票在收入释放日以9.19美元开放,市场上限为1.7302亿美元,P/E比率为91.91美元,贝塔为1.29美元。 The company's stock opened at $9.19 on the earnings release day, with a market cap of $173.02 million, a P/E ratio of 91.91, and a beta of 1.29. 一名分析师维持了“买入”评级,标价为16.00美元。 An analyst maintained a "buy" rating with a $16.00 price target.